drug
lanadelumab
Marketedupdated 3mo agoby Takeda Pharmaceuticals USA Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying lanadelumab
- —A Survey of Lanadelumab in Participants With Hereditary Angioedema
- phase3A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)
- phase3A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor
- phase3A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
- —Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 47m ago
Found something off?
comments(0)
5-min edit window · permanent after that